Of note, within the T2D group, we have also tested donors that had developed single T1D-associated antibodies against insulin (mIAA; n = 10, mean age = 47; Supplementary Table S1), most likely in response to subcutaneous insulin injection, as all T2D-IAA+ donors had received insulin therapy before or during hospitalization. The gene discussed is INS; the disease is type 2 diabetes mellitus.